Clinical Evaluation of the Photoallergy Potential of Atralin Gel
Information source: Coria Laboratories, Ltd.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: Atralin (tretinoin) gel, 0.05% (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Coria Laboratories, Ltd. Official(s) and/or principal investigator(s):
Joseph W Stanfield, MS, Principal Investigator, Affiliation: Suncare Research Laboratories
Summary
To assess the potential of tretinoin gel 0. 05% and its vehicle to produce photoallergic
reactions, measured as skin reactions following induction and challenge.
Clinical Details
Official title: Clinical Evaluation of the Photoallergy Potential of Atralin Gel (Tretinoin Gel 0.05%)
Study design: Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)
Primary outcome: UV Induced skin irritation
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Normal, healthy volunteers
- 18 years of age and older
Exclusion Criteria:
- Less than 18 years of age
Locations and Contacts
Suncare Research Laboratories, Winston-Salem, North Carolina 27106, United States
Additional Information
Starting date: January 2008
Last updated: May 5, 2008
|
